Quantum BioPharma Expands Reach With New unbuzzd Launch and Cutting-Edge MS Clinical Study
Quantum makes waves in Puerto Rico’s beverage market and pioneers advanced MS diagnostic tool.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) is making headlines in April, launching its innovative alcohol detox drink, unbuzzd™, in Puerto Rico and initiating a groundbreaking clinical study aimed at revolutionizing the diagnosis and treatment monitoring of multiple sclerosis (MS).
Revolutionary Beverage Hits Puerto Rico
Celly Nutrition, a licensee of Quantum BioPharma, introduced unbuzzd, a beverage designed to rapidly metabolize alcohol, restore mental clarity, and significantly reduce hangover symptoms, to the Puerto Rican market. The new product is hitting Puerto Rico’s shelves in collaboration with FUSION Distribution Group, a well-established distributor of health-conscious food and beverage brands across the Caribbean region.
John Duffy, CEO of Celly Nutrition, commented on the launch, stating:
The launch of unbuzzd in Puerto Rico represents a significant milestone for unbuzzd and the latest step towards our goal of making unbuzzd more widely available at retail. We are proud to work with FUSION as we expand to Puerto Rico and then to markets across the Caribbean.
This strategic move will position unbuzzd alongside popular brands such as Celsius (NASDAQ: CELH) Energy Drinks, SHINE Water, Tona Cerveza, Goli, POWER CRUNCH, and Kin Whiskey. FUSION’s distribution network is impressive, covering major retailers like Walmart (NYSE: WMT), Walgreens (NASDAQ: WBA), Costco (NYSE: COST), Sam’s, Farmacias Caridad, Pueblo Supermarkets, and Supermax. Additionally, consumers can expect to find unbuzzd in grocery stores, pharmacies, convenience stores, bars, restaurants, hotels, and even country clubs throughout Puerto Rico.
Eduardo Santacana, CEO of FUSION, expressed enthusiasm about the launch: “The FUSION team is very excited to launch unbuzzd across the Caribbean, beginning with Puerto Rico. unbuzzd will be available in grocery, pharmacy, and convenience stores, as well as in hotels, bars, country clubs, and restaurants. Our goal is to place unbuzzd within arm’s reach of every consumer in Puerto Rico.”
Beyond its appealing consumer promise, unbuzzd is scientifically validated through rigorous clinical research. Recently completed double-blind, placebo-controlled studies confirm that unbuzzd significantly accelerates alcohol metabolism and effectively reduces blood alcohol concentration levels. Available in convenient powder stick packs, it aims to attract health-conscious individuals seeking enjoyable yet responsible drinking experiences.
In addition, unbuzzd ready-to-mix sticks are available for purchase in 3-pack, 8-pack, and 18-pack formats at Amazon and unbuzzd.com.
Also Read: Quantum BioPharma Expands unbuzzd™ Retail Push, Doubles Down on Bitcoin
Advancing MS Diagnosis With Innovative PET Imaging
Meanwhile, Quantum BioPharma has taken another significant leap forward in medical innovation by partnering with Massachusetts General Hospital (MGH) in a clinical study. This groundbreaking research focuses on a novel Positron Emission Tomography (PET) imaging technique designed to visualize and measure myelin integrity in MS patients, potentially transforming how MS is monitored and treated.
Dr. Pedro Brugarolas, principal investigator at MGH, explained the technology behind the study: “[18 F]3F4AP is a radiolabeled form of the drug dalfampridine, which binds to K+ channels in demyelinated axons. As such, we are interested to study its potential as a biomarker to identify and monitor responders to remyelinating and neuroprotective treatments for MS, and we are excited to undertake this important work with Quantum BioPharma.”
Quantum BioPharma’s Vice-President of Scientific and Clinical Affairs, Dr. Andrzej Chruscinski, emphasized the importance of this innovation, stating:
We are very excited about the potential of this novel PET biomarker to directly visualize and measure demyelination in the central nervous system. We expect that this biomarker will be an important diagnostic tool in future MS trials investigating therapies that can prevent demyelination and promote remyelination. This is very relevant to our Lucid-MS clinical development program as Lucid-MS has been shown to protect the myelin sheath and prevent demyelination in animal models of MS.
The partnership underscores Quantum BioPharma’s continued commitment to pioneering new solutions for neurodegenerative diseases. Zeeshan Saeed, CEO of Quantum BioPharma, commented on the partnership’s significance: “We are glad to be part of this study and working with this team of scientists and physicians at Mass General in developing this PET tracer as a biomarker in MS.”
Also Read: Quantum BioPharma Reports Completion of Phase 1 Clinical Trial for MS Drug Lucid-21-302
Strategic Growth in Wellness and Healthcare
These dual advancements mark Quantum BioPharma’s strategic push into both consumer health and serious neurological treatment domains. While unbuzzd appeals to a broad demographic of health-minded drinkers, the PET imaging study targets a critical gap in medical diagnostics, offering new hope to patients battling multiple sclerosis.
Quantum BioPharma continues to leverage strategic collaborations and scientific research to drive innovation. Its commercial ventures, like unbuzzd, complement its clinical initiatives, highlighting a versatile and growth-oriented strategy aimed at diverse markets. Investors and consumers alike will undoubtedly watch closely as Quantum BioPharma reshapes both the beverage industry and medical diagnostics.
Whether providing relief from the discomfort of hangovers or pioneering revolutionary medical imaging techniques, Quantum BioPharma remains steadfast in pushing boundaries and redefining standards of innovation in both the wellness and healthcare sectors.
Read Next: How This $4 Stock is Taking on Wall Street’s Big Banks with a $700 Million Lawsuit
Join the Discussion in the WVC Facebook Investor Group
Do you have a stock tip or news story suggestion? Please email us at Invest@WealthyVC.com.
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.
Wealthy VC and its employees are not Registered Investment Advisors, Broker-Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Wealthy VC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Wealthy VC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Our website and newsletter are for entertainment purposes only. This website is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
Release of Liability: Through the use of this email and/or website advertisement, by viewing or using it, you agree to hold Wealthy VC, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Wealthy VC-sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Wealthy VC or an offer or solicitation to buy or sell any security. WealthyVC and our controlling entity 1000724287 Ontario Ltd have been compensated USD $20,000 for social media marketing and USD $7,500 per month for 3 months for investor relations by Quantum BioPharma Ltd.
None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Wealthy VC strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D and all reports published on SEDAR if the company featured is Canadian. Wealthy VC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors with a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day’s closing price and the high of-day price during our promotional coverage.
In preparing this publication, Wealthy VC has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, Wealthy VC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Wealthy VC is not responsible for any claims made by the companies advertised herein, nor is Wealthy VC responsible for any other promotional firm, its program or its structure.
